Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
    Future Virol. 2011 Sep;6(9):1045-1058.

    Oncolytic poliovirus against malignant glioma.

    Source

    Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA.

    Abstract

    In cancerous cells, physiologically tight regulation of protein synthesis is lost, contributing to uncontrolled growth and proliferation. We describe a novel experimental cancer therapy approach based on genetically recombinant poliovirus that targets an intriguing aberration of translation control in malignancy. This strategy is based on the confluence of several factors enabling specific and efficacious cancer cell targeting. Poliovirus naturally targets the vast majority of ectodermal/neuroectodermal cancers expressing its cellular receptor. Evidence from glioblastoma patients suggests that the poliovirus receptor is ectopically upregulated on tumor cells and may be associated with stem cell-like cancer cell populations and proliferating tumor vasculature. We exploit poliovirus' reliance on an unorthodox mechanism of protein synthesis initiation to selectively drive viral translation, propagation and cytotoxicity in glioblastoma. PVSRIPO, a prototype nonpathogenic poliovirus recombinant, is scheduled to enter clinical investigation against glioblastoma.

    PMID:
    21984883
    [PubMed]
    PMCID:
    PMC3187927
    Free PMC Article

    Images from this publication.See all images (7)Free text

    Figure 1
    Figure 2
    Figure 3
    Figure 5
    Figure 6
    Figure 7
    Figure 4

      Supplemental Content

      Icon for PubMed Central

      Save items

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk